Seventy percent of newly diagnosed bladder cancers are classified as non‐muscle‐invasive
bladder cancer (NMIBC) and are often associated with high rates of recurrence that require …

Non‐muscle‐invasive bladder cancer (NMIBC) represents the vast majority of bladder
cancer diagnoses, but this definition represents a spectrum of disease with a variable …

Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75–
85% of patients with bladder cancer present with a disease that is confined to the mucosa …

Aim This review article summarizes the current clinical practice guidelines around disease
definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer …

Purpose: Although associated with an overall favorable survival rate, the heterogeneity of
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …

Bladder cancer is divided into two entities: non-muscle-invasive (NMIBC) and muscle
invasive bladder cancer. NMIBC represents 75% of primary diagnoses and is characterized …

Objective To summarize the discussion at a public workshop, cosponsored by the US Food
and Drug Administration (FDA) and the American Urological Association, reviewing potential …

Bladder cancer is one of the most common cancer diagnoses in the United States, with an
estimated 68,810 new cases in 2010, accounting for 7% of all cancers and 3% of cancer …

Objective Non–muscle-invasive bladder cancer (NMIBC) comprises a wide spectrum of
tumors with different behaviors and prognoses. It follows that the surveillance for these …

In 2008, bladder cancer was estimated to be the fourth most common male cancer
accounting for 6% of all cancers and the eighth highest cancer-related mortality rate in …